<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01611025</url>
  </required_header>
  <id_info>
    <org_study_id>MISP39134</org_study_id>
    <nct_id>NCT01611025</nct_id>
  </id_info>
  <brief_title>Hospital Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic Over Time</brief_title>
  <official_title>The Impact on the Hospital's Microbial Ecology Follow the Introduction of Ertapenem and Other Newly Introduced Antibiotic, Using Antibiotic Utilization and Hospital Susceptibility Data Over Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Veterans General Hospital, Taiwan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective, multicentre, observational study to assess the trends in antibiotic&#xD;
      utilization and hospital ecology with respect to susceptibility patterns of selected&#xD;
      bacterial isolates to the utilized antibiotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective, multicentre, observational study to assess the trends in antibiotic&#xD;
      utilization and hospital ecology with respect to susceptibility patterns of selected&#xD;
      bacterial isolates to the utilized antibiotics.&#xD;
&#xD;
      There will be two sets of data collected: Hospital acquired infection (only the first&#xD;
      pathogen cultured of each episode) and All infection (the whole hospital susceptibility data)&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        1. To study the impact of the introduction of ertapenem on the susceptibility pattern of&#xD;
           various pathogens to imipenem/meropenem.&#xD;
&#xD;
        2. To study the impact of the introduction of ertapenem on the susceptibility of all Gram&#xD;
           negative bacilli to antimicrobial agents commonly used in the participated study sites.&#xD;
&#xD;
        3. To explore the trend in antimicrobial utilization before and after the introduction of&#xD;
           new antimicrobial agents to the hospital formulary during the index period.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To study the trend of antimicrobial susceptibility to ESBL-producing Enterobacteriaceae&#xD;
           during the index period&#xD;
&#xD;
        2. To study the impact of the introduction of other newly introduced antibiotics (e.g.,&#xD;
           tigecycline) on the susceptibility pattern of various pathogens to carbapenems&#xD;
&#xD;
        3. To study the prevalence and trend of Pan drug resistant Acinetobacter baumannii and&#xD;
           Pseudomonas aeruginosa resistant during the index period&#xD;
&#xD;
      Exploratory objectives:&#xD;
&#xD;
      1) To explore the resistant rates of ESBL-producing Enterobacteriaceae, Pan drug resistant&#xD;
      Acinetobacter baumannii and Pseudomonas aeruginosa in different hospitals after adjusted DDD.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. There will be no increase in the utilization rates of other antibiotics, specifically&#xD;
           the other carbapenem drugs (imipenem, meropenem) in the index period (2-3 years before&#xD;
           and 2-3 years after the introduction of ertapenem).&#xD;
&#xD;
        2. The introduction of ertapenem to the institution formulary will not negatively impact&#xD;
           the susceptibility of selected bacterial isolates to the other carbapenem antibiotics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">30000</enrollment>
  <condition>Infectious Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        selected bacterial isolates, such as but not limited to Pseudomonas aeruginosa,&#xD;
        Acinetobacter Baumannii and Enterobacteriaceae species&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  the susceptibility of Pseudomonas aeruginosa&#xD;
&#xD;
          -  the susceptibility of Escherichia coli (ESBL and Non-ESBL producing strains)&#xD;
&#xD;
          -  the susceptibility of Klebsiella pneumoniae(ESBL and Non-ESBL producing strains)&#xD;
&#xD;
          -  the susceptibility of Enterobacter cloacae&#xD;
&#xD;
          -  the susceptibility of Enterobacter aerogenes&#xD;
&#xD;
          -  the susceptibility of Acinetobacter baumannii&#xD;
&#xD;
          -  antibiotic utilization data of carbapenems: Ertapenem, Meropenem, Imipenem&#xD;
&#xD;
          -  antibiotic utilization data of Penicillins: Piperacillin/Tazobactam&#xD;
&#xD;
          -  antibiotic utilization data of cephalosporins: Ceftriaxone, Cefotaxime, Flomoxef,&#xD;
             Cefoperazone, Ceftazidime, cefepime, Cefpirome&#xD;
&#xD;
          -  antibiotic utilization data of Aztreonam,&#xD;
&#xD;
          -  antibiotic utilization data of fluoroquinolones: Ciprofloxacin, Levofloxacin&#xD;
&#xD;
          -  antibiotic utilization data of aminomethylcyclines: Tigecycline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu-Der Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>October 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <last_update_submitted>June 1, 2012</last_update_submitted>
  <last_update_submitted_qc>June 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

